澳大利亚10年队列研究:他汀类药物使用与青光眼发病风险的关联
该研究基于澳大利亚45岁以上人群的10年队列数据,采用巢式病例对照设计,发现他汀类药物的总体使用与青光眼发病无显著关联(OR 1.04,95%CI 0.97-1.11),但长期使用超过3年者风险升高(OR 1.12,95%CI 1.04-1.21),且风险仅见于瑞舒伐他汀使用者(OR 1.11,95%CI 1.01-1.22)。
要点
- 他汀总体使用与青光眼发病无显著关联(OR 1.04,95%CI 0.97-1.11)。
- 使用他汀超过3年者青光眼风险升高(OR 1.12,95%CI 1.04-1.21)。
- 瑞舒伐他汀使用者青光眼风险升高(OR 1.11,95%CI 1.01-1.22)。
核心结论
- 长期使用他汀类药物与青光眼发病风险升高相关,但风险仅见于瑞舒伐他汀使用者。
研究设计与样本
- 基于澳大利亚45岁以上人群大规模队列的巢式病例对照研究,随访期为2009-2016年。
- 青光眼发病定义为至少三次抗青光眼药物索赔记录,对照按年龄、性别和心血管疾病匹配。
主要发现
- 病例组他汀使用者比例为40.5%,对照组为38.4%。
- 调整基线特征和纵向索赔记录后,他汀使用与青光眼发病无显著关联(OR 1.04,95%CI 0.97-1.11)。
- 他汀使用超过3年相比不足1年者青光眼发病风险升高(OR 1.12,95%CI 1.04-1.21)。
- 瑞舒伐他汀使用者青光眼发病风险升高(OR 1.11,95%CI 1.01-1.22),其他他汀无显著关联。
关键数值与推荐
- 他汀使用超过3年 vs 不足1年:OR 1.12,95%CI 1.04-1.21。
- 瑞舒伐他汀使用:OR 1.11,95%CI 1.01-1.22。
临床怎么用
- 对长期使用他汀尤其是瑞舒伐他汀的患者,可提示关注青光眼筛查。
- 他汀总体使用不增加青光眼风险,不应因此停用他汀。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SYNOPSIS: In a cohort of middle-aged and elderly Australians, we found that long-term statin use was associated with a higher risk of glaucoma onset. As to subtypes of statins, the increased risk was only found in rosuvastatin users. PURPOSE: To investigate the relationship between statin use and glaucoma onset in a 10-year longitudinal study. METHODS: This nested case-control study was based on data from a large-scale cohort of Australians aged over 45 years old. Medication exposure was identified by claims records from the Pharmaceutical Benefits Scheme during the follow-up period (2009-2016). The onset of glaucoma was defined as the people with at least three claims of antiglaucoma medications. Controls matched by age, gender and cardiovascular diseases were selected from participants without prescription of antiglaucoma medications. A conditional logistic regression model was used to assess the association between statin use and glaucoma onset. RESULTS: The proportion of statin users was higher in the case group (40.5%) than that in the control group (38.4%). After adjusting for baseline characteristics and longitudinal claims records, statin use was not associated with glaucoma onset (OR 1.04, 95% CI 0.97 to 1.11). However, an increased risk of glaucoma onset was observed in participants with a longer duration of statin use (>3 years vs <1 year: OR 1.12, 95% CI 1.04 to 1.21). With respect to specific types of statins, participants taking rosuvastatin were more likely to suffer from glaucoma (OR 1.11, 95%CI 1.01 to 1.22). The use of other statins was not significantly associated with glaucoma onset. CONCLUSIONS: Long-term statin use was found to be associated with a higher risk of glaucoma onset in this study. Regarding specific types of statins, the increased risk of glaucoma onset was only observed in users of rosuvastatin.
引用
- Yuan Y, Wang W, Shang X, et al. Association between statin use and the risks of glaucoma in Australia: a 10-year cohort study. Br J Ophthalmol. 2021. PMID: 34348924. doi:10.1136/bjophthalmol-2021-318789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。